Fulgent Genetics Inc (FLGT)
Cash ratio
Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash and cash equivalents | US$ in thousands | 55,144 | 58,042 | 65,111 | 54,677 | 97,473 | 84,076 | 58,348 | 66,172 | 79,506 | 168,770 | 138,780 | 353,069 | 164,894 | 214,877 | 100,461 | 151,461 | 87,426 | 53,031 | 2,431 | 9,302 |
Short-term investments | US$ in thousands | 202,962 | 155,027 | 246,595 | 251,018 | 326,681 | 383,726 | 400,083 | 805,146 | 773,377 | 749,236 | 376,622 | 725,227 | 770,652 | 255,102 | 676,578 | 258,317 | 344,443 | 50,939 | 18,530 | 61,322 |
Total current liabilities | US$ in thousands | 72,899 | 73,990 | 75,751 | 75,949 | 73,018 | 61,421 | 64,819 | 107,848 | 116,178 | 124,385 | 127,527 | 152,630 | 112,840 | 147,158 | 129,130 | 196,530 | 131,074 | 60,356 | 8,872 | 7,953 |
Cash ratio | 3.54 | 2.88 | 4.11 | 4.03 | 5.81 | 7.62 | 7.07 | 8.08 | 7.34 | 7.38 | 4.04 | 7.06 | 8.29 | 3.19 | 6.02 | 2.09 | 3.29 | 1.72 | 2.36 | 8.88 |
December 31, 2024 calculation
Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($55,144K
+ $202,962K)
÷ $72,899K
= 3.54
The cash ratio of Fulgent Genetics Inc has shown fluctuations over the period from March 31, 2020, to December 31, 2024. The cash ratio measures the company's ability to cover its current liabilities with its cash and cash equivalents. A higher cash ratio indicates a stronger ability to meet short-term obligations.
Initially, the cash ratio was high at 8.88 on March 31, 2020, demonstrating a strong liquidity position. However, it decreased significantly to 1.72 by September 30, 2020, which could indicate potential liquidity challenges or a decrease in cash holdings relative to current liabilities.
Subsequently, the cash ratio improved to 8.29 by December 31, 2021, reaching a similar high level as in March 2020. This suggests a recovery in liquidity or an increase in cash reserves. However, the ratio fluctuated in the following periods but generally remained above 2, indicating adequate liquidity levels to cover short-term obligations.
The cash ratio peaked at 8.08 on March 31, 2023, before gradually decreasing to 3.54 by December 31, 2024. While the ratio experienced some volatility, it generally remained at levels that indicate Fulgent Genetics Inc has a sufficient amount of cash to cover its short-term liabilities.
Overall, the trend in the cash ratio for Fulgent Genetics Inc reflects fluctuations in its liquidity position over the analyzed period, with some periods showing stronger liquidity and others indicating potential challenges that may need monitoring and management attention.
Peer comparison
Dec 31, 2024